Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

被引：0

作者：

Kanamori, Masayuki ^{[1
]}

Tsuzuki, Shunsuke ^{[2
]}

Shibahara, Ichiyo ^{[3
]}

Saito, Kuniaki ^{[4
]}

Shimoda, Yoshiteru ^{[1
]}

Tanaka, Kazuhiro ^{[5
]}

Yamaguchi, Shigeru ^{[6
]}

Natsumeda, Manabu ^{[7
]}

Matsutani, Tomoo ^{[8
]}

Hanihara, Mitsuto ^{[9
]}

Nakada, Mitsutoshi ^{[10
]}

Kuroda, Jun-Ichiro ^{[11
]}

Matsuda, Masahide ^{[12
]}

Yoshimoto, Koji ^{[13
]}

Yonezawa, Ushio ^{[14
]}

Sonoda, Yukihiko ^{[15
]}

Takano, Koji ^{[16
]}

Yonezawa, Hajime ^{[17
]}

Otani, Yoshihiro ^{[18
]}

Nakahara, Yukiko ^{[19
]}

Uchida, Masashi ^{[20
]}

Nonaka, Masahiro ^{[21
]}

Mineharu, Yohei ^{[22
]}

Kitamura, Yohei ^{[23
]}

Yamashita, Shinji ^{[24
]}

Yamauchi, Takahiro

Miyake, Yohei ^{[26
]}

Deguchi, Shoichi ^{[27
]}

Beppu, Takaaki ^{[28
]}

Tamura, Kaoru ^{[29
]}

Koizumi, Shinichiro ^{[30
]}

Hirose, Yuichi ^{[31
]}

Asano, Kenichiro ^{[32
]}

Hiruta, Ryo ^{[33
]}

Kinoshita, Manabu ^{[34
]}

Miyake, Keisuke ^{[35
]}

Nakayama, Noriyuki ^{[36
]}

Inoue, Akihiro ^{[37
]}

Ono, Takahiro ^{[38
]}

Sasaki, Takahiro ^{[39
]}

Akiyama, Yukinori ^{[40
]}

Fukami, Shinjiro ^{[41
]}

Yoshino, Atsuo ^{[42
]}

Kawanishi, Yu ^{[43
]}

Asanome, Taku ^{[44
]}

Yamaguchi, Takuhiro ^{[25
,45
]}

Takahashi, Masamichi ^{[46
]}

Yamasaki, Fumiyuki ^{[14
]}

Arakawa, Yoshiki ^{[22
]}

Narita, Yoshitaka ^{[46
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, 1-1 Seiryo Cho,Aoba Ku, Sendai, Japan

[2] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Japan

[4] Kyorin Univ Facil Med, Dept Neurosurg, Tokyo, Japan

[5] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Japan

[6] Hokkaido Univ, Fac Med, Dept Neurosurg, Sapporo, Japan

[7] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan

[8] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan

[9] Univ Yamanashi, Dept Neurosurg, Yamanashi, Japan

[10] Kanazawa Univ, Dept Neurosurg, Kanazawa, Japan

[11] Kumamoto Univ, Fac Life Sci, Dept Neurosurg, Kumamoto, Japan

[12] Univ Tsukuba, Inst Med, Dept Neurosurg, Tsukuba, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan

[15] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Japan

[16] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[17] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan

[18] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan

[19] Saga Univ, Fac Med, Dept Neurosurg, Saga, Japan

[20] St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa, Japan

[21] Kansai Med Univ, Dept Neurosurg, Hirakara, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[23] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan

[24] Univ Miyazaki, Fac Med, Dept Clin Neurosci, Div Neurosurg, Miyazaki, Japan

[25] Univ Fukui, Fac Med Sci, Dept Neurosurg, Div Med, Fukui, Japan

[26] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Japan

[27] Shizuoka Canc Ctr, Div Neurosurg, Nagaizumi, Japan

[28] Iwate Med Univ, Dept Neurosurg, Shiwa, Japan

[29] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan

[30] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Japan

[31] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Japan

[32] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Hirosaki, Japan

[33] Fukushima Med Univ, Dept Neurosurg, Fukushima, Japan

[34] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan

[35] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan

[36] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan

[37] Ehime Univ, Sch Med, Dept Neurosurg, Toon, Japan

[38] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan

[39] Wakayama Med Univ, Sch Med, Dept Neurol Surg, Wakayama, Japan

[40] Sapporo Med Univ, Dept Neurosurg, Sapporo, Japan

[41] Tokyo Med Univ, Dept Neurosurg, Tokyo, Japan

[42] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan

[43] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Kochi, Japan

[44] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Japan

[45] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Japan

[46] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

来源：

NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期

关键词：

Asian population; determinant of use; glioblastoma; survival; tumor-treating fields; PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; RESECTION; EFFICACY; CRITERIA; EXTENT; TRIAL; WAFER;

D O I：

10.1093/noajnl/vdae176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results. Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions. TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

引用

页数：11

共 50 条

[31] A PHASE II STUDY OF TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED, UNRESECTABLE GLIOBLASTOMA
Sumrall, Ashley
Haggstrom, Daniel
Burri, Stuart
Symanowski, James
NEURO-ONCOLOGY, 2017, 19 : 16 - 16
[32] Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis
Guzauskas, Gregory F.
Pollom, Erqi L.
Stieber, Volker W.
Wang, Bruce C.
Garrison, Lou
CANCER RESEARCH, 2018, 78 (13)
[33] Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial
Taphoorn, Martin J. B.
Dirven, Linda
Kanner, Andrew A.
Lavy-Shahaf, Gitit
Weinberg, Uri
Taillibert, Sophie
Toms, Steven A.
Honnorat, Jerome
Chen, Thomas C.
Sroubek, Jan
David, Carlos
Idbaih, Ahmed
Easaw, Jacob C.
Kim, Chae-Yong
Bruna, Jordi
Hottinger, Andreas F.
Kew, Yvonne
Roth, Patrick
Desai, Rajiv
Villano, John L.
Kirson, Eilon D.
Ram, Zvi
Stupp, Roger
JAMA ONCOLOGY, 2018, 4 (04) : 495 - 504
[34] A PROSPECTIVE STUDY OF TUMOR-TREATING FIELDS COMBINED WITH SYSTEMIC THERAPY IN RECURRENT GLIOBLASTOMA
Guo, C.
Yang, Q.
He, Z.
Duan, H.
Lu, J.
Ke, C.
Xie, H.
Chen, Z.
Liu, R.
Zhang, X.
Mou, Y.
NEURO-ONCOLOGY, 2024, 26
[35] A PROSPECTIVE STUDY OF TUMOR-TREATING FIELDS COMBINED WITH SYSTEMIC THERAPY IN RECURRENT GLIOBLASTOMA
Guo, Chengcheng
Yang, Qunying
He, Zhenqiang
Duan, Hao
Lu, Jie
Cao, Xi
Sai, Ke
Ke, Chao
Chen, Zhenghe
Liu, Ruhua
Zhang, Xiangheng
Mou, Yonggao
NEURO-ONCOLOGY, 2024, 26
[36] Safety of Tumor Treating Fields and Concomitant Radiation Therapy for Newly Diagnosed Glioblastoma in a Pilot Study
Grossman, R.
Bukstein, F.
Blumenthal, D.
Ben Harosh, C.
Limon, D.
Ram, Z.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E223 - E223
[37] Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma
Goldlust, Samuel A.
Singer, Samuel
Cappello, Lori A.
AlMekkawi, Ahmad K.
Lee, Kangmin D.
Ingenito, Anthony C.
Lewis, Brett E.
Nyirenda, Themba
Azmi, Hooman
Kaptain, George J.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[38] TUMOR TREATING FIELDS AND RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY RESULTS FROM A PILOT STUDY
Grossman, R.
Bokstein, F.
Ben Harosh, C.
Blumenthal, D.
Limon, D.
Ram, Z.
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[39] TUMOR TREATING FIELDS THERAPY IN A NEWLY DIAGNOSED GLIOBLASTOMA PATIENT WITH MULTIPLE SCLEROSIS
Kassubek, R.
Ludolph, A. C.
NEURO-ONCOLOGY, 2018, 20 : 242 - 242
[40] Nationwide Characteristics of Providers Utilizing Tumor Treating Fields for Newly Diagnosed Glioblastoma
McClelland, S., III
Sosanya, O.
Mitin, T.
Degnin, C.
Chen, Y.
Attia, A.
Suh, J. H.
Jaboin, J. J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E302 - E303

← 1 2 3 4 5 →